Omashu® is approved for the treatment of moderate to severe persistent allergic asthma in patients aged 15 years and above whose symptoms cannot be effectively controlled after treatment with inhaled corticosteroids and long-acting β2-receptor agonists, providing a new treatment option for many allergic asthma patients.
Let us work together to protect precious health